[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523280":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":19,"armGroups":11,"interventions":11,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":11,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of stage IV melanoma patients who decide to enroll in a clinical research",null,"3 months",{"measure":14,"description":11,"timeFrame":15},"Rate of stage IV melanoma patients who remain in clinical trial to trial completion","12 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":18,"maskingInfo":11},"CASE_CROSSOVER","PROSPECTIVE","Patients with stage IV melanoma who are actively considering enrolling in a clinical study for said condition, but have not yet completed enrollment and randomization.",[21],{"name":22,"affiliation":5,"role":23},"Michael B Gill","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","415-900-4227","bask@withpower.com",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Power Life Sciences","San Francisco","California","94107","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":45},"https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100523280","investigating-participation-patterns-among-stage-iv-melanoma-patients-100523280",false,"NCT06093594","Investigating Participation Patterns Among Stage IV Melanoma Patients","Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Diagnosis of stage IV melanoma\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Inability to perform regular electronic reporting","ALL","18 Years",{"count":58,"type":59},500,"ESTIMATED","OBSERVATIONAL","Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.\n\nThe main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.",[63],"Stage IV Melanoma",[63],"NOT_YET_RECRUITING","2023-10-16",{"date":68,"type":69},"2023-10-23","ACTUAL",{"date":71,"type":59},"2024-11",{"date":73,"type":59},"2026-11",{"name":5,"class":6},1]